OPCH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Option Care Health to CD&R and McKesson
Globe Newswire•13/10/2026•09:00 ET
0
Key Highlights
- ➤Option Care Health sale proposed at $32.05 per share in cash
- ➤UBS target $39.00 and J.P. Morgan target $33.00 before announcement
- ➤Sale price below Option Care Health’s 52-week high of $36.80
- ➤Wohl & Fruchter investigating board approval and transaction disclosures
Expert Statements
Joshua Fruchter, Founding partner of Wohl & Fruchter
“We are investigating whether the OPCH Board of Directors acted in the best interests of OPCH shareholders in approving the sale”
Joshua Fruchter, Founding partner of Wohl & Fruchter
“This includes whether the cash consideration agreed upon is fair to OPCH shareholders, and whether all material information regarding the transaction has been fully disclosed.”
Joshua Fruchter, Founding partner of Wohl & Fruchter
“We encourage OPCH shareholders to contact us if they have any concerns.”
MONSEY, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Option Care Health, Inc. (NASDAQ: OPCH) (“OPCH”) to CD&R and McKesson Corporation for $32.05 per share in cash.
Notably, the sale price is below the price targets for OPCH of at least two Wall Street analysts before the sale was announced: A.J. Rice of UBS ($39.00 per share) and Lisa Gill of J.P. Morgan ($33.00 per share) (Source: TipRanks).
Get started
Create a free account to read the full story.